期刊文献+

格列奈类促泌剂的临床认识 被引量:5

The clinical experience of glinides
原文传递
导出
摘要 格列奈类促泌剂是国内常用的非磺脲类胰岛素促泌剂,主要包括瑞格列奈和那格列奈。文章将从其在国内外的应用、降糖效果、不良反应、与胰岛素的合用、在CKD中的使用以及用药原则等方面阐述对格列奈类药物的临床认识。 Glinides are nonsulfonylurea insulin secretagogues which are commonly used in China, mainly including repaglinide and nateglinide. In the article, the clinical experience of glinides will be stated including its application at home and abroad, hypoglycemic effect, adverse effect, the combination with insulin, the application in the patients with CKD, the medication principle, and so on.
作者 李娟 童南伟
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2014年第10期959-961,共3页 Chinese Journal of Practical Internal Medicine
关键词 格列奈类药物 瑞格列奈 那格列奈 2型糖尿病 glinides repaglinide nateglinide type 2 diabetes
  • 相关文献

参考文献9

  • 1American Diabetes Association.Standards of Medical Care in Diabetes-2014[J].Diabetes Care,2014,37(suppl 1):14-80.
  • 2International Diabetes Federation.Global Guideline for Type 2 Diabetes,2012.
  • 3International Diabetes Federation.Managing Older People with Type 2 Diabetes Global Guideline,2013,Geneva .
  • 4American Association of Clinical Endocrinologists.Medical Guideline for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan[J].Endocrine Practice,2011,17(suppl 2):1-53.
  • 5Wang W,Bu R,Su Q,et al.Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy[J].Expert Opin Pharmacother,2011,12(18):2791-2799.
  • 6Lund SS,Tarnow L,Frandsen M,et al.Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes:12 month,randomised,double blind trial[J].BMJ,2009,339:b4324.
  • 7郭晓蕙.2型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识[J].中国糖尿病杂志,2013,21(10):865-870. 被引量:57
  • 8U.K.Prospective Diabetes Study Group.Overview of 6 Years’ Therapy of Type Ⅱ Diabetes:A Progressive Disease [J].Diabetes,1995,44(11):1249-1258.
  • 9Rahier J,Guiot Y,Henquin JC,et al.Pancreatic b-cell mass in European subjects with type 2 diabetes[J].Diabetes,Obesity and Metabolism,2008,10 (Suppl 4),32-42.

二级参考文献38

  • 1全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:699
  • 2陈崴,王辉,董秀清,何惠娟,刘庆华,骆宁,谭嘉庆,林建雄,聂静,毛海萍,陈维清,余学清.广州市城区普通人群中慢性肾脏病的流行病学研究[J].中华肾脏病杂志,2007,23(3):147-151. 被引量:172
  • 3Taal MW, Chertow GM, Marsden PA, el al. Brenner c. Ree tor's The Kidney. 9th ed. Philadelphia, PA= Saunders Elsevi- er, 2012.
  • 4Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China N Engl J Med, 2010,362:1090-1101.
  • 5Fox CS, Larson MG, I.eip EP, et al. Predictors of new-onset kidney disease in a community based population. JAMA,2004, 291 : 84,1-850.
  • 6Zhang 1., Zhang P, Wang F, et al. Prevalence and factors as- sociated with CKD: a population study from Beijing. Am J Kid- ney Dis, 2008, 51:373-384.
  • 7Zhang L, Wang F, Wang L, et al. Prevalence of chronic kid- ney disease in China: a cross sectional survey, Lancei, 2012, 379:815-822.
  • 8National Kidney Foundation. KI)O'QI Clinical practice guide- lines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis, 2007,49(suppl 2): S1 -S180.
  • 9Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diahetes mellitus in the United States. Clin Ther, 2009, 31:2608-2617.
  • 10Lu B, Song X, Dong X, et al. High prevalence of chronic kid ney disease in populatiowhased patients diagnosed with type 2 diabetes in downtown Shanghai. J Diabetes Complications, 2008,22:96- 103.

共引文献56

同被引文献64

  • 1秦颖.二甲双胍临床应用概述[J].继续医学教育,2012,26(3):46-48. 被引量:14
  • 2Ji L N,Lu J M,Guo X H,et al.Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables[J].BMC Public Health,2013,13:602.
  • 3De Fronzo R A.Banting Lecture.From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellitus[J].Diabetes,2009,58(4):773-795.
  • 4Inzucchi S E,Bergenstal R M,Buse J B,et al.Management of hyperglycemia in type 2 diabetes,2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care,2015,38(1):140-149.
  • 5Feldman J M.Glyburide:a second-generation sulfonylurea hypoglycemic agent.History,chemistry,metabolism,pharmacokinetics,clinical use and adverse effects[J].Pharmacotherapy,1985,5(2):43-62.
  • 6Kwong S C,Brubacher J.Phenformin and lactic acidosis:a case report and review[J].J Emerg Med,1998,16(6):881-886.
  • 7Nasri H,Rafieian-Kopaei M.Metformin:Current knowledge[J].J Res Med Sci,2014,19(7):658-664.
  • 8Campbell R K,White J R Jr,Saulie B A.Metformin:a new oral biguanide[J].Clin Ther,1996,18(3):360-371.
  • 9UK Prospective Diabetes Study(UKPDS)Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)[J].Lancet,1998,352(9131):854-865.
  • 10Lalloyer F,Staels B.Fibrates,glitazones,and peroxisome proliferator-activated receptors[J].Arterioscler Thromb Vasc Biol,2010,30(5):894-899.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部